FATE - Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Biopharma companies can certainly test even a long-term investor's patience, given that these are the kind of investments that can take quite awhile to bloom. Years of clinical trials, scrutinized results, and a hoped-for (but not guaranteed) approval from the U.S. Food and Drug Administration are all part of the lifecycle. If clinical trials repeatedly fall short of expectations or an FDA approval fails to materialize, it can be money down the drain for shareholders. If a breakthrough happens, however, it can make investors very rich.
Fate Therapeutics (NASDAQ: FATE) is hoping for the latter result for its immunotherapy treatments of B-cell lymphoma -- cancer that forms in a person's white blood cells. But after its latest clinical trial results, is the company's stock a nice pick for bargain hunters? Or is this a sign to get out while you can?
Image source: Getty Images.
For further details see:
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain